<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134547">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350128</url>
  </required_header>
  <id_info>
    <org_study_id>PT001002</org_study_id>
    <nct_id>NCT01350128</nct_id>
  </id_info>
  <brief_title>PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-Blind, Chronic Dosing (7 Days), Three-Period, Six-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Four Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Atrovent® HFA Inhalation Aerosol (Open-Label) as An Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to determine an optimal dose and dosing regimen of
      PT001 MDI for further evaluation in later stage studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate efficacy relative to placebo of PT001
      MDI in patients with moderate to severe chronic obstructive pulmonary disease (COPD) within
      the range of doses evaluated in this protocol. To this end, each dose of PT001 MDI will be
      compared to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to
      baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12</measure>
    <time_frame>7 days</time_frame>
    <description>FEV1 AUC0-12 relative to baseline following chronic dosing (1 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak change in FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Highest value of FEV1 post-dose on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to reach ≥10% improvement on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak improvement in Inspiratory Capacity (IC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak improvement in inspiratory capacity on Day 1</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium Bromide HFA Inhalation Aerosol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ipratropium Bromide HFA Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PT001 Placebo MDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 MDI</intervention_name>
    <description>PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium Bromide HFA Inhalation Aerosol</intervention_name>
    <description>Taken as 2 inhalations of the 17 µg per actuation strength MDI QID</description>
    <arm_group_label>Ipratropium Bromide HFA Inhalation Aerosol</arm_group_label>
    <other_name>Atrovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Matching placebo to PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 23, 2013</lastchanged_date>
  <firstreceived_date>May 5, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>May 16, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
